ArticleSurgical endoscopy2025
Comparison of endoscopic papillectomy and pancreatoduodenectomy for high-grade intraepithelial neoplasia of the duodenal papilla: a retrospective cohort study.
Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endoscopic Papillectomy for Ampullary Tumors in Older Patients: Balancing Oncologic Benefit and Geriatric Risk.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
aimThe objective of this study is to compare the clinical outcomes of endoscopic papillectomy (EP) and pancreatoduodenectomy (PD) for high-grade intraepithelial neoplasia of the duodenal papilla (HGIN-DP) and develop a preoperative risk prediction model for pathological upgrading.
methodsRetrospective analysis of 92 patients (43 EP vs. 49 PD) treated between 2014 and 2023. Propensity score matching (1:1) balanced baseline characteristics, yielding 62 matched cases. Univariate and multivariate logistic regression analysis identified risk factors for pathological upgrading. A nomogram was developed and validated using patient data.
resultsPD demonstrated superior 5-year overall survival (88.5% vs. 61.2%, P < 0.05) but longer operative time (230.0 vs. 41.0 min), higher blood loss (250.0 vs. 1.0 mL), prolonged hospitalization (27.0 vs. 8.0 days), increased costs (CNY 71,116.0 vs. 25,898.0), and higher delayed gastric emptying rates (35.5% vs. 3.2%) compared to EP. Postoperative pathological upgrading occurred in 51.2% (EP) and 69.4% (PD) of cases. Among them, 29.0% were diagnosed with adenocarcinoma in the EP group and 38.7% in the PD group. Multivariate analysis identified age (OR = 1.11), platelet count (OR = 1.02), and tumor size > 1 cm (OR = 21.79) as risk factors for pathological upgrading. A nomogram incorporating these predictors showed strong discriminative accuracy (AUC = 0.91 training, 0.86 validation).
conclusionEP offers advantages in recovery and cost, while PD remains preferable for HGIN-DP patients with high-risk features. The validated prediction model aids preoperative risk stratification, guiding personalized treatment decisions.
Indexed as
Identifiers
40854993What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.